MX2018009503A - Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, metodos de preparacion y usos. - Google Patents
Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, metodos de preparacion y usos.Info
- Publication number
- MX2018009503A MX2018009503A MX2018009503A MX2018009503A MX2018009503A MX 2018009503 A MX2018009503 A MX 2018009503A MX 2018009503 A MX2018009503 A MX 2018009503A MX 2018009503 A MX2018009503 A MX 2018009503A MX 2018009503 A MX2018009503 A MX 2018009503A
- Authority
- MX
- Mexico
- Prior art keywords
- trifluoroacetate salt
- crystalline form
- tlr7 agonist
- preparation methods
- tlr7
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
La presente invencion se refiere a una sal de trifluoroacetato de 2-butoxi-7-(4-(pirrolidin-1-ilmetil)bencil)-5H-pirrolo[3,2-d]piri midin-4-amina como agonista de TLR7 (formula I), forma cristalina B de la sal de trifluoroacetato, metodos para preparar la sal de trifluoroacetato y forma cristalina B y usos de la sal de trifluoroacetato y forma cristalina B.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081899.3A CN107043377A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| PCT/CN2017/072894 WO2017133687A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009503A true MX2018009503A (es) | 2018-12-11 |
Family
ID=59500539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009503A MX2018009503A (es) | 2016-02-05 | 2017-02-04 | Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, metodos de preparacion y usos. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10683296B2 (es) |
| EP (1) | EP3412674B1 (es) |
| JP (1) | JP6877450B2 (es) |
| KR (1) | KR102393281B1 (es) |
| CN (2) | CN107043377A (es) |
| AR (1) | AR107550A1 (es) |
| AU (1) | AU2017214135B2 (es) |
| CA (1) | CA3013521C (es) |
| CL (1) | CL2018002101A1 (es) |
| DK (1) | DK3412674T3 (es) |
| EA (1) | EA037048B1 (es) |
| ES (1) | ES2834304T3 (es) |
| HK (1) | HK1259182A1 (es) |
| HU (1) | HUE052210T2 (es) |
| IL (1) | IL260981B (es) |
| MX (1) | MX2018009503A (es) |
| NZ (1) | NZ745023A (es) |
| PH (1) | PH12018501641B1 (es) |
| SG (1) | SG11201806688QA (es) |
| TW (1) | TWI778952B (es) |
| UA (1) | UA121276C2 (es) |
| WO (1) | WO2017133687A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| KR20210013183A (ko) * | 2018-05-25 | 2021-02-03 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Tlr7 작용제 및 폐암을 치료하기 위한 이의 약학 조합물 |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| WO2021177679A1 (ko) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 |
| CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
| CN116056725A (zh) | 2020-08-04 | 2023-05-02 | 蛋白科技先鋒 | 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途 |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| US11999750B2 (en) | 2022-01-12 | 2024-06-04 | Denali Therapeutics Inc. | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| PE20120106A1 (es) | 2008-12-09 | 2012-02-20 | Gilead Sciences Inc | Moduladores de receptores tipo toll |
| WO2012106522A2 (en) | 2011-02-04 | 2012-08-09 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| WO2013103967A1 (en) | 2012-01-05 | 2013-07-11 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| EA202090662A3 (ru) * | 2012-10-10 | 2020-08-31 | Янссен Сайенсиз Айрлэнд Юси | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ |
| ES2632448T3 (es) * | 2012-11-20 | 2017-09-13 | Glaxosmithkline Llc | Nuevos compuestos |
| CN106459058B (zh) * | 2014-05-01 | 2019-07-05 | 诺华股份有限公司 | 作为toll-样受体7激动剂的化合物和组合物 |
| CR20160512A (es) * | 2014-05-01 | 2016-12-21 | Novartis Ag | Compuestos y composiciones como agonistas del receptor tipo toll 7 |
| CN105367576A (zh) | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| DK3190113T3 (da) | 2014-08-15 | 2021-06-07 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2016
- 2016-02-05 CN CN201610081899.3A patent/CN107043377A/zh active Pending
-
2017
- 2017-02-03 TW TW106103697A patent/TWI778952B/zh active
- 2017-02-04 DK DK17747007.7T patent/DK3412674T3/da active
- 2017-02-04 HU HUE17747007A patent/HUE052210T2/hu unknown
- 2017-02-04 ES ES17747007T patent/ES2834304T3/es active Active
- 2017-02-04 CN CN201780009751.1A patent/CN108602833B/zh active Active
- 2017-02-04 SG SG11201806688QA patent/SG11201806688QA/en unknown
- 2017-02-04 WO PCT/CN2017/072894 patent/WO2017133687A1/zh active Application Filing
- 2017-02-04 NZ NZ745023A patent/NZ745023A/en unknown
- 2017-02-04 US US16/075,303 patent/US10683296B2/en active Active
- 2017-02-04 EA EA201891772A patent/EA037048B1/ru not_active IP Right Cessation
- 2017-02-04 AU AU2017214135A patent/AU2017214135B2/en active Active
- 2017-02-04 MX MX2018009503A patent/MX2018009503A/es active IP Right Grant
- 2017-02-04 EP EP17747007.7A patent/EP3412674B1/en active Active
- 2017-02-04 UA UAA201809128A patent/UA121276C2/uk unknown
- 2017-02-04 KR KR1020187024629A patent/KR102393281B1/ko active IP Right Grant
- 2017-02-04 JP JP2018540797A patent/JP6877450B2/ja active Active
- 2017-02-04 CA CA3013521A patent/CA3013521C/en active Active
- 2017-02-06 AR ARP170100299A patent/AR107550A1/es unknown
-
2018
- 2018-08-02 PH PH12018501641A patent/PH12018501641B1/en unknown
- 2018-08-03 CL CL2018002101A patent/CL2018002101A1/es unknown
- 2018-08-05 IL IL260981A patent/IL260981B/en unknown
-
2019
- 2019-01-24 HK HK19101232.5A patent/HK1259182A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501641A1 (en) | Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses | |
| PH12018501643A1 (en) | Tlr7 agonist crystalline form a, preparation method and use thereof | |
| PH12019500930A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| UA122773C2 (uk) | Спосіб одержання (4s)-4-(4-ціано-2-метоксифеніл)-5-етокси-2,8-диметил-1,4-дигідро-1,6-нафтиридин-3-карбоксаміду і його очищення для застосування як фармацевтичного активного інгредієнта | |
| PH12018501644A1 (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
| WO2015110897A3 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| MY183123A (en) | Synthesis of copanlisib and its di hydrochloride salt | |
| MX2018009502A (es) | Metodo para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios. | |
| WO2015068175A3 (en) | An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof | |
| MX2017006200A (es) | Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. | |
| MX2016003958A (es) | Formas solidas de ceftolozano. | |
| MX359069B (es) | Sal y formas cristalinas de inhibidor de quinasa tipo polo-4. | |
| MY185367A (en) | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof | |
| PH12018502246A1 (en) | Substituted fused pyrimidinone compounds | |
| MX2018015990A (es) | Compuestos terapeuticos. | |
| WO2017046816A3 (en) | Process for the preparation of derivatives of benzodioxole | |
| WO2016079757A3 (en) | NOVEL PROCESSES FOR THE PREPARATION OF SUBSTITUTED 5-HYDROXYMETHYL-OXAZOLIDINE-2-ONE | |
| IN2013MU03565A (es) | ||
| UA124942C2 (uk) | Спосіб одержання енантіомерів пірліндолу та їхніх солей | |
| MY197130A (en) | Tlr7 agonist crystalline form a, preparation method and use thereof | |
| IN2014MU00070A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |